Johnson & Johnson Announces Positive Results for OTTAVA Robotic Surgery System

Johnson & Johnson (NYSE:JNJ) announced positive results from the first clinical study of its investigational OTTAVA Robotic Surgical System. The prospective, multicenter FORTE study evaluated the system in Roux-en-Y gastric bypass procedures. Results were presented at a medical conference, boosting the system's prospects for regulatory clearance.

The Product

OTTAVA is a next-generation robotic surgical system designed for greater flexibility and precision in minimally invasive surgeries. It features a modular design for easy integration into existing operating rooms and advanced robotic arms with a wide range of motion.

Pricing and Availability

Johnson & Johnson has not yet disclosed pricing or commercial availability. The company is expected to seek FDA approval within the next year.

Competition

OTTAVA enters a market dominated by Intuitive Surgical's da Vinci system. Competitors include Medtronic and Stryker. Positive clinical results are a key step for JNJ to capture share in this growing market.

Potential Impact on the Company

The robotic surgery market is projected to exceed $20 billion by 2030. Success of OTTAVA could provide a significant new revenue stream for Johnson & Johnson, aligning with its focus on medical device innovation.